Evidence map›Paper›PMID 34455739›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2021

[Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].

H F Wang, Y L Zhang, X L Liu, H L Zhu, R Liang, B C Liu, L Zhou, L Meng, W M Li, Q Jiang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

H F WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
Y L ZhangDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Tumor Hospital, Zhengzhou 450008, China.
X L LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
H L ZhuDepartment of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.
R LiangDepartment of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 510370, China.
B C LiuInstitute of Hematology, Chinese Academy of Medical Science, Tianjin 300020, China.
L ZhouShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
L MengDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
W M LiDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Q JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
Peking University · CNShanghai Institute of Hematology · CNSichuan University · CNSouthern Medical University · CNTongji Hospital · CNUnion Hospital · CNZhengzhou University · CN

Funding

National Natural Science Foundation of China 81770161, 81970140
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdolescentAdultAgedAged, 80 and overChinaCross-Sectional StudiesFemaleHumansImatinib MesylateMaleMiddle AgedYoung AdultImatinib MesylateProtein Kinase InhibitorsDrug switchLeukemia, myeloid, chronicQuestionnairesSocio-demographic characteristicsTreatment responseTyrosine kinase inhibitor

Identifiers

PMID34455739
PMCPMC8408488
OpenAlexW3197681160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.